Plain-English translation of NCT07700862 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study compares two different targets in the brain for a treatment called directional deep brain stimulation (DBS), which uses tiny electrodes to help control tremors in people with tremor-dominant Parkinson's disease. Researchers want to see whether stimulating the posterior subthalamic area (PSA), a newer target, works as well as or better than the standard subthalamic nucleus (STN) target. You would receive the device implant and then try both stimulation targets in carefully controlled phases to help doctors understand which works best for your symptoms.
Currently, the subthalamic nucleus is the standard brain target for deep brain stimulation in Parkinson's disease, but it can cause side effects for some patients. This trial is exploring whether a nearby brain area might offer better symptom relief with fewer problems.
You likely qualify if…
You likely don't qualify if…
You would undergo brain surgery to have the deep brain stimulation device implanted. Over the next 12 months, you would participate in two main phases: first, a 2-month acute phase where doctors test both brain targets in random order to see which you tolerate; then, a 4-month chronic phase where you receive each target for 2 months in a crossover design, plus a final 2-month period trying both targets together. Throughout, you would have regular clinic visits for testing and follow-up care, including assessments of your tremor and any side effects.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
China
Sponsor
Ruijin Hospital
Enrollment target
~32 participants
Started
July 2026
Primary completion
December 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dianyou Li, MD, PhD
Ruijin Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.